Research & Development
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
6 March 2025 - Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
5 March 2025 - Biopharmaceutical companies Jazz Pharmaceuticals plc (Nasdaq:JAZZ) and Chimerix (Nasdaq:CMRX) on Wednesday announced a definitive agreement for Jazz to acquire Chimerix for USD8.55 per ...
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
5 March 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Wednesday introduced NovoCare Pharmacy, a direct-to-patient delivery service offering all dose strengths of Weg...
Genentech announces FDA acceptance of supplemental Biologics License Application for Gazyva to treat lupus nephritis treatment
5 March 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted its supp...
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
4 March 2025 - Clinical-stage biotechnology company Latigo Biotherapeutics announced on Monday that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for LTG-...
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
4 March 2025 - South Korean biopharmaceutical company Celltrion announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for STOBOCLO (CT-P41, denosumab-bmwo) a...